Incidence of Precipitated Withdrawal During a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

Gail D'Onofrio; Kathryn F Hawk; Jeanmarie Perrone; Sharon L Walsh; Michelle R Lofwall; David A Fiellin; Andrew Herring

doi:10.1001/jamanetworkopen.2023.6108

Incidence of Precipitated Withdrawal During a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

JAMA Netw Open. 2023 Mar 1;6(3):e236108. doi: 10.1001/jamanetworkopen.2023.6108.

Authors

Gail D'Onofrio^{1

2

3}, Kathryn F Hawk^{1

3}, Jeanmarie Perrone⁴, Sharon L Walsh⁵, Michelle R Lofwall⁵, David A Fiellin^{1

2

3}, Andrew Herring⁶

Affiliations

¹ Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut.
² Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
³ School of Public Health, Yale School of Medicine, New Haven, Connecticut.
⁴ Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
⁵ Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington.
⁶ Department of Emergency Medicine, Highland Hospital Oakland, Oakland, California.

No abstract available

Plain language summary

This cohort study examines the incidence of precipitated withdrawal comparing traditional sublingual buprenorphine with a 7-day extended-release injectable initiated in the emergency department (ED).

Publication types

Clinical Trial
Research Support, N.I.H., Extramural

MeSH terms

Buprenorphine* / adverse effects
Emergency Service, Hospital
Fentanyl / adverse effects
Humans
Incidence
Narcotic Antagonists

Substances

Buprenorphine
Fentanyl
Narcotic Antagonists

Grants and funding

UG1 DA015831/DA/NIDA NIH HHS/United States